Drugs / Iberdomide
Iberdomide
also known as
CC-220 · Iber · Cc-220 hydrochloride · IBERDOMIDA · IBERDOMIDE (CC220) · iberdomide hydrochloride
Small molecule targets CRBN
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | US (FDA) | — | relapsed/refractory diffuse large B-cell lymphoma | 2026-02-17 | “FDA has accepted a New Drug Application (NDA) for iberdomide” bms.com ↗ |
Trials 51
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05560399 | Feb 2023 → Nov 2026 expected | plasma cell myeloma | Icahn School of Medicine at Mount Sinai | Active not recruiting | No outcome recorded |
| Phase 118 trials | ||||||
| Phase 1 | NCT06896916 | Aug 2025 → Mar 2036 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 1 | NCT06348108 | Jul 2025 → Jul 2027 expected | plasma cell myeloma | Alfred Chung, MD | Recruiting | No outcome recorded |
| Phase 1 | NCT06465316 | Dec 2024 → Dec 2026 expected | plasma cell myeloma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1 | NCT06121843 | Feb 2024 → Aug 2028 expected | plasma cell myeloma | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Recruiting | No outcome recorded |
| Phase 1 | NCT06215118 | Feb 2024 → Nov 2027 expected | plasma cell myeloma | Pfizer | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05899738 | May → Jul 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05169515 | Oct 2022 → Sep 2029 expected | B-cell non-Hodgkin lymphoma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1 | NCT05289492 | May 2022 → Nov 2023 | plasma cell myeloma | iTeos Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT04884035 | Sep 2021 → Dec 2028 expected | B-cell non-Hodgkin lymphoma | Celgene Corporation | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04933747 | Aug 2021 → Jan 2023 | impaired renal function disease | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT04855136 | Jun 2021 → Apr 2025 | plasma cell myeloma | Celgene Corporation | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04464798 | Nov 2020 → Jan 2023 | lymphoma | Celgene Corporation | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03824678 | Feb → Jun 2019 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03294603 | Sep → Oct 2017 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03135509 | May → Jun 2017 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02820935 | Jul → Sep 2016 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02034773 | May → Dec 2013 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01733875 | Nov 2012 → Oct 2013 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1/212 trials | ||||||
| Phase 1/2 | NCT07437963 | Oct 2026 → Sep 2029 expected | ganglioneuroblastoma, neuroblastoma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07601100 | Sep 2026 → Jul 2029 expected | plasma cell myeloma | Dana-Farber Cancer Institute | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06232044 | Apr 2025 → May 2028 | plasma cell myeloma | Alliance for Clinical Trials in Oncology | Suspended | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT06785415 | Mar 2025 → Apr 2031 expected | plasma cell myeloma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06518551 | Nov 2024 → Dec 2029 expected | plasma cell myeloma | Omar Nadeem, MD | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05583617 | Nov 2023 → Jul 2028 expected | plasma cell myeloma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05434689 | Jan 2023 → Aug 2028 expected | plasma cell myeloma | University of Alabama at Birmingham | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05392946 | Aug 2022 → Sep 2026 overdue | plasma cell myeloma | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05199311 | May 2022 → Mar 2027 | plasma cell myeloma | Hackensack Meridian Health | Suspended | No outcome recorded |
| Phase 1/2 | NCT04882163 | Oct 2021 → Apr 2026 | B-cell non-Hodgkin lymphoma | Celgene Corporation | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT03310619 | Dec 2017 → Feb 2023 | diffuse large B-cell lymphoma, follicular lymphoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT02773030 | Oct 2016 → May 2024 overdue | plasma cell myeloma | Celgene Corporation | Active not recruiting | No outcome recorded |
| Phase 215 trials · 1 met primary | ||||||
| Phase 2 | NCT06762769 | Jun 2025 → Nov 2032 expected | smoldering plasma cell myeloma | University College, London | Recruiting | No outcome recorded |
| Phase 2 | NCT05272826 | Dec 2024 → Mar 2028 expected | plasma cell myeloma | Canadian Myeloma Research Group | Recruiting | No outcome recorded |
| Phase 2 | NCT06179888 | Aug 2024 → Oct 2027 | plasma cell myeloma | National Cancer Institute (NCI) | Suspended | No outcome recorded |
| Phase 2 | NCT05896228 | Feb 2024 → Mar 2029 expected | plasma cell myeloma | Benjamin T Diamond, MD | Recruiting | No outcome recorded |
| Phase 2 | NCT06107738 | Dec 2023 → Dec 2027 expected | plasma cell myeloma | Barbara Ann Karmanos Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT05527340 | Dec 2022 → Dec 2029 expected | plasma cell myeloma | PETHEMA Foundation | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05177536 | Jun 2022 → Jan 2026 overdue | plasma cell myeloma | University of Nebraska | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05354557 | Apr 2022 → Apr 2027 expected | plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04998786 | Dec 2021 → Jan 2030 expected | plasma cell myeloma | Nantes University Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04776395 | Jul 2021 → Sep 2027 expected | smoldering plasma cell myeloma | Emory University | Recruiting | No outcome recorded |
| Phase 2 | NCT04564703 | Feb 2021 → Jul 2023 overdue | plasma cell myeloma | Stichting European Myeloma Network | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04392037 | Feb 2021 → Dec 2027 expected | plasma cell myeloma | Amsterdam UMC, location VUmc | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03161483 | Aug 2017 → Aug 2021 | systemic lupus erythematosus | Celgene Corporation | Completed | Met primary |
| Phase 2 | NCT02192489 | Nov 2014 → Jun 2017 | sarcoidosis | Celgene Corporation | Withdrawn | No outcome recorded |
| Phase 2 | NCT02185040 | Sep 2014 → Sep 2018 | systemic lupus erythematosus | Celgene Corporation | Completed | No outcome recorded |
| Phase 35 trials · 1 met primary | ||||||
| Phase 3 | NCT07624513 | Aug 2026 → Oct 2033 expected | plasma cell myeloma | Dana-Farber Cancer Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT06216158 | Apr 2024 → Dec 2028 expected | plasma cell myeloma | University of Heidelberg Medical Center | Recruiting | No outcome recorded |
| Phase 3 | NCT05827016 | Jun 2023 → Mar 2029 expected | plasma cell myeloma | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05558319 | Nov 2022 → Apr 2027 expected | plasma cell myeloma | PETHEMA Foundation | Recruiting | No outcome recorded |
| Phase 3 | NCT04975997 | Jun 2022 → Nov 2027 expected | plasma cell myeloma | Celgene Corporation | Active not recruiting | Met primary |
| Comparator or background therapy1 trial | ||||||
| — | NCT07434960 Background | — | — | Bristol-Myers Squibb | Available | No outcome recorded |
News releases announcing trial results or a regulatory action · 13
| Date | Issuer | Release |
|---|---|---|
| 2026-10-08 | Bristol-Myers Squibb | Results Bristol Myers Squibb Announces ZENBEXUS (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3... bms.com ↗
Results showed ZDd demonstrated a statistically significant improvement in the dual-primary endpoint of progression-free survival (PFS) |
| 2026-09-25 | Bristol-Myers Squibb | Results Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma bms.com ↗
Results presented at IMS 2026 show ZENBEXUS in combination with daratumumab and dexamethasone doubled minimal residual disease-negative complete response rates versus daratumumab, bortezomib and dexamethasone (41.1% vs. 20.7%) |
| 2026-08-13 | Bristol-Myers Squibb | Regulatory U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse bms.com ↗ |
| 2026-02-17 | Bristol-Myers Squibb | Regulatory U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma bms.com ↗
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for iberdomide combined with standard treatment (daratumumab + dexamethasone - IberDd) in patients with relapsed or refractory multiple myeloma (RRMM). |
| 2025-12-01 | Bristol-Myers Squibb | Results Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio bms.com ↗
Iberdomide shows deep and sustained responses in newly diagnosed multiple myeloma |
| 2025-09-23 | Bristol-Myers Squibb | Results Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma bms.com ↗
The safety profile of iberdomide in combination with daratumumab and dexamethasone in this study is generally consistent with previous studies. |
| 2025-06-12 | Bristol-Myers Squibb | Results Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025 bms.com ↗
updated clinical findings on the company’s investigational oral CELMoD™ agents mezigdomide and iberdomide in multiple myeloma, and golcadomide in non-Hodgkin lymphoma |
| 2024-11-19 | Bristol-Myers Squibb | Results Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms bms.com ↗
Updated results from Phase 1/2 CC-220-MM-001 trial supporting clinical and pharmacological activity of iberdomide combined with daratumumab and dexamethasone in transplant-ineligible, newly-diagnosed MM patients, including those with high-risk markers |
| 2023-11-02 | Bristol-Myers Squibb | Results Bristol Myers Squibb’s First Disclosures and New Data at ASH 2023 Highlight Company’s Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology bms.com ↗
New results highlighting the enhanced immune-stimulating activity and combinability of targeted protein degradation agents in the treatment of relapsed or refractory multiple myeloma and non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma |
| 2022-12-12 | Bristol-Myers Squibb | Results Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio bms.com ↗ |
| 2022-05-19 | Bristol-Myers Squibb | Results Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders bms.com ↗
Health-related quality of life data from the Phase 1/2 MM-001 study of iberdomide plus dexamethasone, underscore the potential of CELMoD ® compounds in patients with relapsed or refractory multiple myeloma (EHA). |
| 2021-06-02 | Bristol-Myers Squibb | Results Bristol Myers Squibb Data at EULAR 2021 Highlight Commitment to Driving Advancements Across Multiple Immune-Mediated Rheumatic Diseases bms.com ↗
The study showed beneficial effects on skin manifestations in patients with SLE treated with iberdomide. |
| 2020-11-05 | Bristol-Myers Squibb | Results Bristol Myers Squibb Data at ACR Convergence 2020 Underscore Commitment to Advancing Science for Patients with Difficult-to-Treat Immune-Mediated Diseases bms.com ↗
The study met its primary endpoint of SLE Responder Index (SRI-4) response at Week 24, with a greater treatment response in patients with high Type 1 interferon or Aiolos gene expressions. |
All press releases naming this drug 13 releases
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 55 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iberdomide | “Arm C will test JCAR017 in combination with CC-220 (iberdomide )” NCT03310619 ↗ |
| Known as | CC-220 | “Iberdomide (Iber, CC-220) is a novel cereblon E3 ligase modulator (CELMoD) in development for treatment of multiple myeloma and other conditions.” NCT05434689 ↗17“IBERDOMIDE (CC220) IN MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS” NCT04564703 ↗ “Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID)” NCT05199311 ↗ |
| Known as | Cc-220 hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989927 ↗ |
| Known as | Iber | “The study will test a new combination of 3 drugs: Isatuximab (Isa), Iberdomide (Iber) and Dexamethasone (Dex), in patients who have intermediate or high risk smouldering myeloma.” NCT06762769 ↗2“Iberdomide (Iber, CC-220) is a novel cereblon E3 ligase modulator (CELMoD) in development for treatment of multiple myeloma and other conditions.” NCT05434689 ↗ “Participants will receive Iberdomide (Iber) therapy orally (PO) in capsules as follows:” NCT05896228 ↗ |
| Known as | IBERDOMIDA | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989927 ↗ |
| Known as | IBERDOMIDE (CC220) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989927 ↗ |
| Known as | iberdomide hydrochloride | “PRIMARY OBJECTIVE: I. To determine the overall response rate (ORR) of iberdomide hydrochloride (iberdomide) and iberdomide with dexamethasone in intermediate- and high-risk...” NCT04776395 ↗ |
| Modality | Other / unclassified | “Iberdomide is a novel potent cereblon modulator (CELMoD®) agent” PMID 38521893 ↗ Mar 2024 |
| Route | Oral | “administered orally” NCT01733875 ↗ |
| Target | CRBN | “cereblon (CRBN)-modulating agent” PMID 38776914 ↗ May 2024 |